After effective adjudication, use of AstraZeneca vaccine to be resumed

After being detected as "safe and effective" by the European medical regulator, the AstraZeneca vaccine to be used again in European countries including France, Italy, Spain, Netherlands.

Being speculated from the European Medicines Agency (EMA) after the World health organization and Britain's health watchdog both claimed that there won't be higher blood clot risk and that people should continue to be immunized. EMA's chief Emer Cooke said, after an investigation into the jab, its "committee has come to a clear scientific conclusion: this is a safe and effective vaccine".

There have been 37 reports of blood clots out of more than 17 million people vaccinated in the 27 countries and Britain. The drugmaker said that there is no evidence the vaccine carries an increased risk of clots.

Furthermore, in clinical trials, even though the number of thrombotic events was small, these were lower in the vaccinated group. There has also been no evidence of increased bleeding in over 60,000 participants enrolled.

The AstraZeneca/Oxford COVID-19 vaccine, which is being produced by the Serum Institute of India, is part of the COVID-19 vaccination drive in India. Both, Covishield (AstraZeneca/Oxford) and Covaxin (Bharat Biotech) are currently being administered in the country as part of the drive.

3 views0 comments